{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:45:24Z","timestamp":1792079124842,"version":"4.4.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"\n Importance<\/jats:title>\n Electronic patient-reported outcome (PRO) monitoring has shown benefits in advanced cancer, but data specific to metastatic breast cancer (mBC) remain limited. Fatigue is a common, clinically important, and functionally impairing symptom in mBC, making it a patient-centered target for electronic PRO monitoring.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine whether digital PRO monitoring with alert-based responses reduces fatigue in patients with mBC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter randomized clinical trial was conducted from May 2021 to February 2024, with 12 months of follow-up, at 52 breast cancer centers in Germany and included women aged 18 years or older with mBC who were receiving systemic therapy at any point in the metastatic disease course, had a life expectancy of longer than 3 months, were able to read German, and had smartphone access. Data analysis started in February 2024 and lasted 6 months.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n The intervention group completed weekly PRO questionnaires via a smartphone using validated short forms from the European Organization for Research and Treatment of Cancer computerized adaptive testing core item bank. Automated alerts based on predefined PRO deterioration were emailed to trained local nurses or physicians, who contacted patients by telephone within 48 hours. The control group received usual care with quarterly PRO questionnaires and no alerts.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was fatigue at 6 months. Secondary outcomes included fatigue, physical functioning, and quality of life over 12 months. PROs were reported as standardized T scores.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 2008 patients screened, 924 (46.0%) were randomized, and 909 (45.3%) were included in the primary analysis (median age, 50 years [range, 19-83 years]). Baseline mean (SD) fatigue T scores were 57.6 (9.5) in the intervention group and 60.2 (9.0) in the control group (\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), with baseline PROs assessed after randomization but before group-specific follow-up began. At 6 months, adjusted mean fatigue was 54.5 (95% CI, 53.7- 55.4) vs 59.9 (95% CI, 59.0-60.8), yielding a mean difference of \u22125.4 points (95% CI, \u22126.6 to \u22124.1;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), exceeding the minimal clinically important difference (MCID) of 3.3 points. At 6 months, physical functioning was higher in the intervention group (mean difference, 4.0; 95% CI, 2.6-5.4), exceeding its MCID (3.2), whereas the between-group difference in quality of life was 0.8 points (95% CI, 0.02-1.5), which was less than the MCID of 2.9.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This randomized clinical trial found that digital PRO monitoring was associated with clinically meaningful reductions in fatigue and improved physical functioning. These findings support further evaluation of alert-based PRO monitoring in routine oncology care.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n German Clinical Trials Register:\n DRKS00024015<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2026.2661","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:30:28Z","timestamp":1786030228000},"page":"1069","source":"Crossref","is-referenced-by-count":1,"title":["Electronic Patient-Reported Outcome Monitoring With Alert-Based Interventions in Metastatic Breast Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"Maria M.","family":"Karsten","sequence":"first","affiliation":[{"name":"Department of Gynecology with Breast Center, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimrapat","family":"Gebert","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health at Charit\u00e9\u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Pross","sequence":"additional","affiliation":[{"name":"Department of Gynecology with Breast Center, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Hage","sequence":"additional","affiliation":[{"name":"Department of Gynecology with Breast Center, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Dordevic","sequence":"additional","affiliation":[{"name":"Department of Gynecology with Breast Center, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Stephan","sequence":"additional","affiliation":[{"name":"Department of Gynecology with Breast Center, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"K\u00fchn","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine and Psychotherapy, Theodor-Wenzel-Werk e.V., Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Doppelbauer","sequence":"additional","affiliation":[{"name":"Department of Gynecology with Breast Center, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens-Uwe","family":"Blohmer","sequence":"additional","affiliation":[{"name":"Department of Gynecology with Breast Center, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Fischer","sequence":"additional","affiliation":[{"name":"Center for Patient-Centered Outcomes Research, Department for Psychosomatic Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Rose","sequence":"additional","affiliation":[{"name":"Center for Patient-Centered Outcomes Research, Department for Psychosomatic Medicine, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"P\u00f6hlmann","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health at Charit\u00e9\u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Materne","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health at Charit\u00e9\u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Aagaard","family":"Petersen","sequence":"additional","affiliation":[{"name":"Palliative Care Research Unit, Department of Geriatrics and Palliative Medicine GP, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Pauler","sequence":"additional","affiliation":[{"name":"OnkoZert, Neu-Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ferencz","sequence":"additional","affiliation":[{"name":"OnkoZert, Neu-Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Wesselmann","sequence":"additional","affiliation":[{"name":"Deutsche Gesellschaft f\u00fcr Allgemein und Viszeralchirurgie e.V., Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Breidenbach","sequence":"additional","affiliation":[{"name":"German Cancer Society, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Grittner","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health at Charit\u00e9\u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"Institute of Biometry and Clinical Epidemiology, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kowalski","sequence":"additional","affiliation":[{"name":"German Cancer Society, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"24","key":"coi260040r1","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial.","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"coi260040r2","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41591-025-03507-y","article-title":"Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.","volume":"31","author":"Basch","year":"2025","journal-title":"Nat Med"},{"issue":"7","key":"coi260040r3","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.23.00182","article-title":"Impact of remote symptom monitoring with electronic patient-reported outcomes on hospitalization, survival, and cost in community oncology practice: the Texas two-step study.","volume":"7","author":"Patt","year":"2023","journal-title":"JCO Clin Cancer Inform"},{"issue":"6","key":"coi260040r4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi260040r5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer.","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"coi260040r6","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/s41591-022-01788-1","article-title":"Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial.","volume":"28","author":"Mir","year":"2022","journal-title":"Nat Med"},{"issue":"7","key":"coi260040r7","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.20.02015","article-title":"Phase III randomized controlled trial of eRAPID: ehealth intervention during chemotherapy.","volume":"39","author":"Absolom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"1647","key":"coi260040r8","doi-asserted-by":"publisher","first-page":"n1647","DOI":"10.1136\/bmj.n1647","article-title":"Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART).","volume":"374","author":"Maguire","year":"2021","journal-title":"BMJ"},{"key":"coi260040r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101005","article-title":"Implementation of a remote symptom monitoring pathway in oncology care: analysis of real-world experience across 33 cancer centres in France and Belgium.","volume":"44","author":"Franzoi","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"coi260040r10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","article-title":"Global analysis of advanced\/metastatic breast cancer: decade report (2005-2015).","volume":"39","author":"Cardoso","year":"2018","journal-title":"Breast"},{"issue":"12","key":"coi260040r11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"issue":"8","key":"coi260040r12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.","volume":"33","author":"Di Maio","year":"2015","journal-title":"J Clin Oncol"},{"key":"coi260040r13","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.breast.2017.08.008","article-title":"Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.","volume":"37","author":"M\u00fcller","year":"2018","journal-title":"Breast"},{"issue":"11","key":"coi260040r14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S1470-2045(06)70910-X","article-title":"Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study.","volume":"7","author":"Basch","year":"2006","journal-title":"Lancet Oncol"},{"issue":"5","key":"coi260040r15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.5-5-353","article-title":"Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition.","volume":"5","author":"Curt","year":"2000","journal-title":"Oncologist"},{"issue":"5","key":"coi260040r16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.6004\/jnccn.2008.0036","article-title":"Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy.","volume":"6","author":"Butt","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"coi260040r17","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241240972","article-title":"Fatigue in patients with metastatic breast cancer undergoing single-agent taxane-based chemotherapy: a real-world data global network.","volume":"16","author":"Fabi","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"11","key":"coi260040r18","doi-asserted-by":"publisher","first-page":"3781","DOI":"10.1007\/s00520-018-4244-8","article-title":"Metastatic breast cancer patients\u2019 expectations and priorities for symptom improvement.","volume":"26","author":"Tometich","year":"2018","journal-title":"Support Care Cancer"},{"issue":"1","key":"coi260040r19","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/S1470-2045(14)70380-8","article-title":"Outcomes and endpoints in cancer trials: bridging the divide.","volume":"16","author":"Wilson","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"coi260040r20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"6","key":"coi260040r21","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6601231","article-title":"Performance status score: do patients and their oncologists agree?","volume":"89","author":"Blagden","year":"2003","journal-title":"Br J Cancer"},{"issue":"8","key":"coi260040r22","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension.","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"coi260040r23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials.","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"issue":"1","key":"coi260040r24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13063-024-08025-9","article-title":"Statistical analysis plan for the PRO B study: open-label, superiority randomised controlled trial of alarm-based patient-reported outcome monitoring in patients with metastatic breast cancer.","volume":"25","author":"Gebert","year":"2024","journal-title":"Trials"},{"issue":"1","key":"coi260040r25","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1186\/s13063-021-05642-6","article-title":"PRO B: evaluating the effect of an alarm-based patient-reported outcome monitoring compared with usual care in metastatic breast cancer patients-study protocol for a randomised controlled trial.","volume":"22","author":"Karsten","year":"2021","journal-title":"Trials"},{"key":"coi260040r26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2018.04.016","article-title":"The EORTC CAT core\u2014the computer adaptive version of the EORTC QLQ-C30 questionnaire.","volume":"100","author":"Petersen","year":"2018","journal-title":"Eur J Cancer"},{"key":"coi260040r27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejca.2018.11.023","article-title":"Establishing the European norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core.","volume":"107","author":"Liegl","year":"2019","journal-title":"Eur J Cancer"},{"issue":"11","key":"coi260040r28","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.ejca.2012.02.059","article-title":"Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.","volume":"48","author":"Cocks","year":"2012","journal-title":"Eur J Cancer"},{"issue":"3","key":"coi260040r29","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz037","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer.","volume":"3","author":"Musoro","year":"2019","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"key":"coi260040r30","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.conctc.2018.03.008","article-title":"Different ways to estimate treatment effects in randomised controlled trials.","volume":"10","author":"J","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"issue":"9","key":"coi260040r31","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1200\/JCO.21.01344","article-title":"Patient-reported outcome-based symptom management versus usual care after lung cancer surgery: a multicenter randomized controlled trial.","volume":"40","author":"Dai","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi260040r32","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/annonc\/mdw099","article-title":"Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivors.","volume":"27","author":"Abrahams","year":"2016","journal-title":"Ann Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2852636\/jamaoncology_karsten_2026_oi_260040_1792007365.45521.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:00:49Z","timestamp":1792076449000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2852636"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":32,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2026.2661","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}